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Abstract
Murine leukemia virus (MLV) capsid particles can be efficiently pseudotyped with a variant of the HIV-1 envelope protein (Env)
containing the surface glycoprotein gp120-SU and a carboxyl-terminally truncated transmembrane (TM) protein, with only seven
cytoplasmic amino acids. MLV/HIV pseudotyped vector particles acquire the natural host tropism of HIV-1 and their entry is dependent
on the presence of CD4 and an appropriate co-receptor on the surface of the target cell. We describe here the construction of chimeric
MLV/HIV proviruses containing the truncated HIV envelope gene. The MLV/HIV provirus was generated by direct replacement of the
MLV envelope gene with HIV Env coding sequences either with or without the additional inclusion of the woodchuck hepatitis virus
posttranscriptional regulatory element (WPRE). Chimeric MLV/HIV particles could be generated from transfected 293T cells and were able
to infect CD4/CXCR4-positive target cells. However, the second round of infection of target cells was severely impaired, despite the fact
that the WPRE element enhanced the amount of viral mRNA detected. Viral particles released from infected cells showed reduced HIV Env
incorporation, indicating that additional factors required for efficient replication of MLV/HIV pseudotyped viruses are missing.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Retroviruses are enveloped RNA viruses and can be
broadly divided into two categories, simple and complex
retroviruses. They all contain three major genes: gag, pol
and env, which encode structural proteins and enzymes.
Complex retroviruses, like the human immunodeficiency
virus type-1 (HIV-1), encode additional regulatory and ac-
cessory proteins not found in simple retroviruses like mu-
rine leukemia virus (MLV). The HIV accessory proteins
Nef, Vpr, Vpu, and Vif are not required for viral replication
in tissue culture systems, but are important factors of viral
pathogenesis in vivo (Steffens and Hope, 2001). The regu-
latory proteins Tat (a transactivator of HIV-1 LTR driven
gene expression) and Rev are essential for HIV-1 replica-
tion.
All retroviruses generate a full-length primary transcript
upon transcription from the integrated proviral DNA, which
serves as template for Gag and Pol proteins and is encap-
sidated into progeny virions as genomic RNA. The primary
transcript is also further processed to generate a spliced env
mRNA in simple retroviruses or multiply spliced mRNAs in
complex retroviruses. The HIV-1 Rev protein mediates the
nuclear export of unspliced and incompletely spliced viral
mRNA, which is a prerequisite for the replication of com-
plex retroviruses (Pollard and Malim, 1998).
Murine leukemia virus (MLV) capsid particles can be
efficiently pseudotyped with a variant of the HIV-1, -2, and
SIV envelope protein (Env) containing the surface glyco-
protein gp120-SU and a carboxyl-terminally truncated
transmembrane (TM) protein, with only seven cytoplasmic
amino acids (Mammano et al., 1997; Schnierle et al., 1997;
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Indraccolo et al., 1998; Hohne et al., 1999; Stitz et al.,
2000). MLV/HIV pseudotyped vector particle entry is de-
pendent on the presence of CD4 and an appropriate co-
receptor on the surface of the target cell.
HIV replication in rodent cells is blocked at multiple
steps (Bieniasz et al., 1998). The incompatibility of HIV
Gag with murine cells counteracts efficient HIV assembly
and release of viral particles (Mariani et al., 2000). This is
the major obstacle to the establishment of a murine model of
AIDS. A replication competent MLV/HIV pseudotype virus
may therefore be a good tool to study HIV entry in trans-
genic huCD4 mice (Killeen et al., 1993) and might open the
possibility to construct a chimeric HIV which is able to
replicate and cause an AIDS-like disease in mice.
Results
Construction of MLV/HIV proviruses
In the absence of Rev the HIV-1 Env mRNA has been
described to be inefficiently expressed, since nucleocyto-
plasmic transport, stability, and polysomal loading are im-
paired (Nasioulas et al., 1994). In order to construct an
MLV/HIV pseudotype virus, we replaced the Rev function
by cis-acting elements.
It has been previously reported that the presence of an
intron upstream of the HIV-1 Env coding region makes Env
expression Rev independent (Hammarskjold et al., 1994).
We reasoned that the MLV splice sites should serve as an
excisable intron, producing the same effect. We found that
expression of a truncated HIV Env and the subsequent
formation of MLV/HIV pseudotyped vectors was possible
using the MLV signal peptide and the expression vector
pSG5 (Green et al., 1988), which contains the -globin
intron upstream of the env gene (data not shown). This
indicated that the direct replacement of the MLV Env in the
MLV genome with the sequence of the truncated HIV Env
should be possible.
The post-transcriptional regulatory elements of hepadna
viruses promote nuclear export of intron-containing RNA
via cellular transport factors and may improve gene expres-
sion by modification of polyadenylation or translation
(Huang et al., 1999). We therefore added to a second con-
struct the woodchuck hepatitis virus post-transcriptional
regulatory element (WPRE) (Popa et al., 2002), which has
been described to enhance the expression of transgenes
delivered by retroviral vectors (Zufferey et al., 1999).
The MLV/HIV provirus construct pUCX/C7s retains the
MLV splice donor/acceptor sites and the MLV signal pep-
tide for expression of the HIV Env protein (Fig. 1A). The
expected splicing pattern is depicted in Fig. 1B. The MLV
intron, which is spliced out to generate the Env mRNA, was
intended to substitute the Rev function. The construct
pUCX/C7s-WPRE carries in addition the WPRE sequences
3 of the HIV Env sequences to enhance the expression of
the viral mRNA (Fig. 1A).
Formation of infectious particles from transfected 293T
cells
The proviral constructs were co-transfected with the
green fluorescent protein (GFP) encoding retroviral vector
pSFG-EGFP (Lindemann et al., 1997) into 293T cells. The
Fig. 1. Schematic presentation of the MLV/HIV proviral constructs (A) and the spliced mRNAs derived from them (B). C, ClaI; H, HpaI; H3, HindIII; X,
XhoI; SD, splice donor; SA, splice acceptor.
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packagable GFP gene was included in equimolar amounts in
order to be able to monitor the infection of target cells by
GFP expression using MLV/HIV as a helper virus. CD4/
CXCR4-positive NIH3T3 cells (Deng et al., 1997) could be
efficiently transduced with viral supernatants. Table 1 sum-
marizes the infectious titers for the MLV/HIVs, which were
in the range of wt MLV. The average values of three
independent experiments are given. Further infection of
target cells in a second round with supernatants collected 2
days after the infection of NIH3T3 CD4/CXCR4 cells was
strongly impaired. Virus derived from pUCX/C7s could
never be propagated during the second round of infection.
The titers for pUCX/C7s-WPRE dropped significantly dur-
ing the second infection and only a few GFP positive cells
could be observed, which could not be measured by FACS
and were counted directly. The second infection was not
significantly impaired for wt MLV. Further propagation in a
third round of infection was not possible for the MLV/HIV
chimeric viruses and in infected cells, which were cultured
for several weeks, viral replication could not be observed.
Similarly, human CD4/CXCR4-positive cells, including
HeLa-CD4, Jurkat, and MT-4, could be infected in a first
round, but no further propagation of the virus was possible
(data not shown). This indicates that the defect in efficient
viral replication is not due to impaired viral assembly in
mouse cells as described for HIV (Mariani et al., 2000).
Characterization of the MLV/HIV mRNA
To investigate the reasons for the lack of a productive
infection with MLV/HIV pseudovirions, we extracted total
mRNA from infected NIH3T3 CD4/CXCR4 cells and ana-
lyzed it by Northern blot. MLV infected NIH3T3 CD4/
CXCR4 cells displayed a full-length genomic RNA and the
spliced env mRNA detected with a DNA probe derived
from MLV env (Fig. 2A, lane 1). In contrast, an increase in
the spliced form of the viral RNA and an overall weak
expression was detected for pUCX/C7s infected cells with a
probe derived from HIV env (Fig. 2B, lane 1). Using the
same probe, this pattern was reversed in pUCX/C7s-WPRE
infected cells, which displayed an increased expression of
the full-length transcript and an overall higher mRNA ex-
pression (Fig. 2B, lane 2). In addition, a faster migrating
band was detectable in pUCX/C7s-WPRE infected cells,
which might arise from an undefined splice site in the env
sequences or from sequences of the env-WPRE border. This
indicates that the defect in productive replication of virus
derived from pUCX/C7s could arise from the low amounts
of genomic RNA present in infected cells, which might
account for the loss of infectivity in the second round of
infection.
Virus derived from pUCX/C7s-WPRE showed a correct
splicing pattern and elevated mRNA levels. Therefore, the
impairment in replication must be due to other mechanisms.
MLV/HIV protein expression and particle formation in
transfected and infected cells
We analyzed protein expression of HIV-1 Env and MLV
Gag in either transfected 293T producer cells or infected
NIH3T3 CD4/CXCR4 cells to investigate the formation of
viral particles from the proviral DNAs. Figure 3 presents the
Western blot analysis of cell lysates and pelleted viral par-
ticles from transfected 293T cells. HIV-1 Env expression
was detectable in cell lysates (Fig. 3A, lanes 1, 2) and Env
was processed into SU and TM as in cell lysates from the
MLV/HIV packaging cell line FLY-HIV-87 (Fig. 3A, lane
5) (Thaler and Schnierle, 2001). After longer exposure
gp120 was also detectable in pUCX/C7s transfected 293T
cell lysates (data not shown). Particle formation was ana-
lyzed by pelleting supernatants derived from transfected
293T cells. Gp120 (Fig. 3B, lanes 2,3) and MLV p30 Gag
(Fig. 3B, lanes 1–4) were detectable, which indicates the
formation of MLV/HIV pseudotyped particles. As a control,
the blots were stripped and incubated with an antibody
directed against the MLV Env gp70. Only in MLV
(pMOV-3 (Harbers et al., 1981)) transfected cell lysates
(Fig. 3A, lane 3) and pelleted viral particles (Fig. 3B, lane
4) is gp70 detectable.
Subsequently, we analyzed cell lysates of infected
NIH3T3 CD4/CXCR4 cells for the expression of HIV Env
Table 1
Construct transfected into
293T cells
First round of
infection on NIH3T3
CD4/CXCR4 cells
Second round of
infection on NIH3T3
CD4/CXCR4 cells
pMOV-3 (MLV) 7.5  104 1.7  104
pUCX/C7s 2.5  104 1
pUCX/C7s-WPRE 4.2  104 100
Vector DNA 1 1
Note. Titers are given in infectious units per ml (IU/ml).
Fig. 2. Northern blot analysis of MLV/HIV infected NIH3T3 CD4/CXCR4
cells; 15 g (MLV/HIV) and 18 g (MLV wt) mRNA from infected
NIH3T3 CD4/CXCR4 cells were analyzed by Northern blot analysis. (A)
MLV RNA was detected with a MLV env DNA probe (corresponding to
positions 6537–7769 in MLV) after 2 h exposure. (B) MLV/HIV RNA was
detected with a probe derived from HIV env 3.1 kb XhoI–SalI fragment
from pLAc/env-Tr712-neo (Wilk et al. 1992) after 16 h exposure. Un-
treated cells served as a negative control.
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and its incorporation into viral particles generated thereof.
In cell lysates, only the precursor gp140 could be detected.
Longer exposure of the blot did not allow the detection of
gp120 (Fig. 4A, lanes 1, 2). Supernatants of infected
NIH3T3 CD4/CXCR4 cells were analyzed for the formation
of viral particles. Although MLV Gag was present in higher
Fig. 3. Western blot analysis of pUCX/C7s and pUCX/C7s-WPRE transfected 293T cells and viral particles. Equal amounts of cell lysates were analyzed
by Western blot. Expression of HIV-1 Env was detected with an anti-gp120 antibody (Dunn Labtech, Ansbach, Germany) and anti-goat HRP-coupled
secondary antibody, and MLV Gag (p30) was detected with a polyclonal rabbit serum as described before (Schnierle et al., 1997). MLV Env was detected
with a polyclonal goat serum as described before (Erlwein et al., 2003). (A) Cell lysates of pUCX/C7s and pUCX/C7s-WPRE transfected 293T cells. (B)
Pelleted viral particles of pUCX/C7s and pUCX/C7s-WPRE from transfected 293T cells. 293T cells transfected with the vector pSFG-EGFP (Lindemann
et al., 1997) served as a negative control. Cell lysates of FLY-HIV-87 cells (Thaler and Schnierle, 2001) were loaded as a marker for HIV Env processing.
The precursor gp140 and the cleaved form of Env gp120 are indicated.
Fig. 4. Western blot analysis of pUCX/C7s and pUCX/C7s-WPRE infected NIH3T3 CD4/CXCR4 cells and viral particles. Equal amounts of cell lysates were
analyzed by Western blot. Expression of HIV-1 Env, MLV Gag, and MLV Env was detected as described above. (A) Cell lysates of pUCX/C7s and
pUCX/C7s-WPRE infected NIH3T3 CD4/CXCR4 cells. (B) Pelleted viral particles from pUCX/C7s and pUCX/C7s-WPRE infected NIH3T3 CD4/CXCR4
cells. NIH3T3 CD4/CXCR4 cells infected with the vector pSFG-EGFP (Lindemann et al., 1997) served as a negative control. In B, lane 5, some material
from lane 4 has been leaking into lane 5 and, due to the high amounts of MLV Env present, gave a signal with the anti-gp70 antibody. Cell lysates of
FLY-HIV-87 cells (Thaler and Schnierle, 2001) were loaded as a marker for HIV Env processing. The precursor gp140 and the cleaved form of Env gp120
are indicated.
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amounts in pelleted particles from infected cells than in
those from transfected 293T cells (Fig. 3, lanes 2–4). HIV
Env was barely detectable in particles derived from pUCX/
C7s-WPRE (Fig. 4B, lane 3) and undetectable in pUCX/C7s
infected cells (Fig. 4B, lane 2). Vector particles derived
from pUCX/C7s-WPRE infected cells showed similar
amounts of Env in the Western blot analysis (Fig. 4B, lane
3) as particles derived from pUCX/C7s transfected 293T
cells (Fig. 3B, lane 2). However, the corresponding Gag
signal was higher from infected cells (Fig. 4B, lane 3),
indicating that less HIV Env per viral particle is present in
particles released from infected cells. This demonstrates that
infected NIH3T3 CD4/CXCR4 cells produce viral particles
that contain no or very low amounts of HIV Env, which
decreases their infectivity. On the contrary, MLV infected
cells did not display this Env incorporation defect. MLV
Env expression was drastically increased in infected
NIH3T3 cells (Fig. 4A, lane 3) and high amounts of Env
were detected from pelleted viral particles (Fig. 4B, lane 4)
as a result of viral replication in these cells.
It has been shown that VSV-G expressed by target cells
is able to induce membrane fusion with defective particles
(Vogt et al., 2001). We therefore used supernatants from
infected NIH3T3 CD4/CXCR4 cells to infect VSV-G
expressing cells (Ory et al., 1996) and could observe
transduction of these cells with pUCX/C7s-WPRE and
pUCX/C7s derived supernatants (data not shown). Corre-
spondingly, MLV/HIV infectivity should be rescued by
expression of a functional envelope protein by the infected
target cells. NIH3T3 CD4/CXCR4 cells were transfected
with an expression construct for the Mo-MLV Env (Schni-
erle et al., 1996). Two days after transfection, NIH3T3
CD4/CXCR4 or NIH3T3 CD4/CXCR4 cells expressing
Mo-MLV Env were infected with MLV/HIV generated
from 293T cells as described above. Both target cells could
be infected with equal efficiencies (Fig. 5A and B). After an
additional 2 days, supernatants of these infected cells were
used to infect NIH3T3 CD4/CXCR4 cells to monitor the
formation of infectious particles released from the different
target cells (Fig. 5C and D). Mo-MLV Env expression in the
Fig. 5. Rescue of MLV/HIV infectivity by expression of Mo-MLV Env in target cells. NIH3T3 CD4/CXCR4 cells either transfected with an expression
construct for Mo-MLV Env (Schnierle et al., 1996) or untransfected were infected with MLV/HIV generated from 293T cells by co-transfection of the
proviral genomes and an GFP encoding retroviral vector. Infection was monitored by the resulting shift to green fluorescence (eGFP) by FACS analysis (A,
B). Supernatants of these infected cells were used to infect NIH3T3 CD4/CXCR4 and the formation of infectious particles was monitored by GFP expression
(C, D). FACS analysis was performed with FACScan (Becton Dickinson, Heidelberg) using Cellquest software.
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target cells successfully rescued the infectivity of particles
derived from pUCX/C7s-WPRE and pUCX/C7s infected
NIH3T3 CD4/CXCR4 cells (Fig. 5D). On the contrariety,
MLV infection was not influenced by the Mo-MLV Env
expression in the target cells (Fig. 5, lower panel). These
experiments confirm that functional Gag-Pol is being pro-
duced in infected cells and that the function of the HIV
envelope glycoprotein is impaired.
In addition, NIH3T3 CD4/CXCR4, HeLa-CD4, and
Jurkat cells were transfected with both MLV/HIV con-
structs, but a productive infection of these cells was never
observed.
Discussion
We replaced the Env gene of MLV with a truncated HIV
Env variant, which has only seven cytoplasmic amino acids,
to generate a chimeric MLV/HIV. Infectious viral particles
could be produced from transfected 293T cells, but a pro-
ductive viral replication in CD4/CXCR4-positive cells did
not take place. Multiple reasons account for this defect in
infectivity of MLV/HIV viruses.
The construct pUCX/C7s was generated by direct re-
placement of the Env sequences and it was hoped that the
MLV intron allows proper HIV Env expression. Although
infectious viral particles could be generated by transfection
of 293T cells with pUCX/C7s DNA, infected cells released
only few viral particles, as detected by anti-Gag Western
blot analysis of viral particles (Fig. 4B, lane 2). Only low
amounts of genomic mRNA with higher levels of the
spliced Env mRNA could be detected in infected cells,
which explains the decrease in particle formation, since the
viral capsid proteins are encoded by the genomic mRNA. In
addition, no HIV Env incorporation into these viral particles
could be detected, which makes the particles noninfectious.
The MLV intron was therefore not a suitable substitute for
the Rev function, which is needed by HIV for adequate
distribution of single to multiple spliced mRNA.
Inclusion of the WPRE sequences in the MLV/HIV ge-
nome (pUCX/C7s-WPRE) however leads to efficient viral
mRNA expression and a correct splicing pattern in pUCX/
C7s-WPRE virus infected cells (Fig. 2B). This indicates that
the WPRE sequences are suitable for replacement of the
Rev function in this context. The amount of viral particles
released by pUCX/C7s-WPRE infected cells was therefore
increased compared to the previous construct. The amounts
of Gag detected in pelleted viral particles derived from
infected cells was slightly higher (Fig. 4B, lane 3) than in
particles derived from transfected 293T cells (Fig. 3B, lane
3). However, viral particles released from pUCX/C7s-
WPRE infected cells had only very low amounts of HIV
Env incorporated (Fig. 4B, lane 3), which lead to a severe
reduction in viral titers in the second round of infection and
resulted finally in an abortive infection.
It is tempting to speculate that the CD4 and co-receptor
expression of the infected cells is responsible for the MLV/
HIV replication defect. Transfected 293T cells displayed
the Env precursor gp140 as well as the processed form of
Env gp120/gp20. However, the Env precursor gp140 was
predominantly detected in Western blot analysis of cell
lysates of infected NIH3T3 CD4/CXCR4 cells, indicating
that receptor expression might interfere with proper Env
processing. We performed a vector rescue assay with MLV/
HIV particles generated by co-transfection of 293T cells
with VSV-G and infected with the same batch of VSV-G
pseudotyped virus either NIH3T3 CD4/CXCR4 or NIH3T3
cells containing a GFP encoding vector genome. Rescue of
the GFP encoding vector genome was not altered in
NIH3T3 CD4/CXCR4 cells or NIH3T3 cells and shows that
receptor expression is not responsible for the replication
defect of pUCX/C7s or pUCX/C7s-WPRE derived virus.
Our findings are reminiscent of data published for a HIV
variant containing the same truncated HIV Env. This HIV
variant replicates in a cell-type-dependent fashion, retaining
its in vitro infectivity in MT-4 cells (Wilk et al., 1992) but
not in other cell lines. The truncated Env is inefficiently
incorporated into viral particles in such nonpermissive cells
(Freed and Martin, 1996; Yu et al., 1993). It is currently
believed that the interaction of the HIV matrix protein (MA)
and the long cytoplasmic tail of HIV Env facilitates Env
incorporation into viral particles, but the reasons why the
truncated Env is incorporated in MT-4 cells are not known.
Another HIV variant has been recently described which
carries a truncated HIV Env and has had the matrix protein
replaced by the MLV MA (Reed et al., 2002) to avoid the
HIV Gag specific assembly defect in murine cells (Mariani
et al., 2000). This HIV variant efficiently assembled, but
failed to replicate in murine cells. However, it did replicate
with delayed kinetics in human MT-4 cells, indicating that
additional mutations have occurred to allow replication.
Although we have cultured our MLV/HIV pseudoviruses
for up to 6 weeks on MT-4 cells, we have as yet been unable
to detect viral replication. Additional adaptations might also
be required for MLV/HIV to be able to replicate in MT-4
cells.
Conclusive reasons for the defect in incorporation of the
truncated HIV Env observed by us and others (Freed and
Martin, 1996; Yu et al., 1993; Iwatani et al., 2001; Reed et
al., 2002) are not known, but they must affect a general
mechanism during retroviral budding, e.g., lipid raft local-
ization. Not only HIV Env incorporation into HIV particles
but also into MLV particles in a viral context is impaired.
Although we were able to construct a MLV/HIV, which
generates properly spliced viral mRNA by inclusion of the
WPRE sequences into the MLV/HIV genome, viral repli-
cation will require additional modifications of the cytoplas-
mic tail of HIV Env. It might for instance be helpful to
retain the palmitoylation sites to promote Env targeting to
lipid rafts (Rousso et al., 2000). Recently, a diaromatic
motif (YW) present in the gp41 cytoplasmic domain has
been described to be required for retrograde transport of
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Env to the trans-Golgi network (TGN). A virus mutated in
the YW motif was poorly infectious and presented a defect
in Env incorporation, supporting a model in which retro-
grade transport of Env is implicated in the optimization of
fully infectious HIV-1 production (Blot et al., 2003). Inclu-
sion of the diaromatic motif might also improve MLV/HIV
production. A modified virus might be suitable for use in
transgenic mice as a low cost model for HIV infection.
On the other hand, the data demonstrate nicely that the
generation of replication competent retroviruses (RCRs) by
recombination of MLV/HIV vectors with HIV Env is very
unlikely and illustrate the safety of the MLV/HIV vector
system (Thaler and Schnierle, 2001).
Materials and methods
Plasmids
The MLV/HIV proviral constructs were generated by
subcloning a SalI–ClaI fragment of the MLV genome
pMOV-3 (Harbers et al., 1981) (position 3705–7674 (Shin-
nick et al., 1981)) into pBluescript (Stratagene), generating
the construct pBS-S/C. A HpaI–ClaI fragment (position
5816–7674) was replaced by the corresponding sequences
of the construct pSG-X/C7s, generating the construct pBS-
S/C-HIV. The construct pSG-X/C7s contains a fusion of the
MLV Env signal peptide and the HIV Env (aa 1–712 of the
mature Env protein). It was generated by insertion of a
2.2-kb PCR fragment, which was produced by the primers
HIV-Xho (gat ctc gag aca gaa aaa ttg tgg gtc aca gtc) and
HIV-ClaI (gat atc gat cat tca cta cag aaa gta cag caa aaa c)
using the HIV Env expression construct pLAc/env-Tr712-
neo (Wilk et al., 1992) as a template, into the XhoI and the
ClaI site of the plasmid pwt(HX) (Erlwein et al., 2002).
The chimeric MLV/HIV provirus pUCX/C7s was gen-
erated by insertion of the HIV env containing the ClaI
fragment (4980–7674) from pBS-S/C-HIV into the MLV
genome. The construct pUCX/C7s encodes for the gag/pol
genes of MLV and the truncated variant of the HIV-1
envelope gene which was used previously to generate ret-
roviral vectors (Schnierle et al., 1997). The construct
pUCX/C7s-WPRE was generated by insertion of the WPRE
sequences as a ClaI fragment into the unique nonmethylated
ClaI site of the construct pUCX/C7s.
Transfections and transduction assays
The proviral constructs (8 g) were co-transfected with
the green fluorescent protein (GFP) encoding retroviral vec-
tor pSFG-EGFP (4 g) (Lindemann et al., 1997) into 293T
cells utilizing the “Superfect” reagent (Qiagen, Hilden, Ger-
many) according to the manufacturer’s instructions. For
10-cm dishes, 293T cells were seeded at a density of 1.5 
106 and transfected using 12 g total DNA. Two days after
transfection, the supernatant was collected, filtered through
a 0.45-m-pore filter (Millipore, Eschborn, Germany), and
used for infections or analyzed for Env incorporation into
viral particles. Target cells were seeded in six-well plates at
a density of 5  104 cells per well the day before infection.
Viral supernatant was added and incubated for 48 h. Trans-
duction efficiency was analyzed by monitoring the expres-
sion of GFP by fluorescence-activated cell sorting (FACS-
can, Becton Dickinson, Heidelberg) using the Cellquest
software or by directly counting GFP-positive cells under
the fluorescent microscope during the second round of in-
fection.
Preparation of viral proteins and immunoblots
The incorporation of Env proteins into the viral particles
was analyzed using supernatants of transfected 293T cells
or infected NIH3T3 CD4/CXCR4 cells filtered through a
0.45-m filter (Greiner, Frickenhausen, Germany) and
stored at 80°C. Virus particles were pelleted through a
30% sucrose cushion for 90 min at 35,000 rpm in an SW41
rotor. Western blot analysis was performed as described
before (Schnierle et al., 1997). The HIV Env proteins were
detected by incubation with goat antiserum against gp120
(Dunn Labtech, Ansbach, Germany), followed by incuba-
tion with a horseradish peroxidase-labeled anti-goat anti-
body. MLV Env gp70 was detected with a polyclonal goat
serum as described before (Erlwein et al., 2003). Protein
bands were finally visualized by enhanced chemilumines-
cence detection using the ECL kit (Amersham, Braun-
schweig, Germany) according to the manufacturer’s instruc-
tions.
Northern blot analysis
Total cellular mRNA was prepared from NIH3T3 CD4/
CXCR4 cells 2 days after infection with MLV/HIV or MLV
viral particles generated by transfection of 293T cells, using
the Peqlab kit (PeqLab, Erlangen, Germany) according to
the manufacturer’s instructions; 15 g (MLV/HIV) and 18
g (MLV wt) total mRNA were separated on a denaturating
agarose gel and transferred to Hybond (Ambion, Miton
Abingdon, UK) membrane. DNA probes for mRNA detec-
tion were labeled using the stripable DNA kit (Ambion,
Miton Abingdon, UK). MLV genomic RNA and the spliced
env mRNA were detected with a DNA probe derived from
MLV env (corresponding to positions 6537–7769 in MLV).
MLV/HIV mRNA was detected using a probe derived from
HIV env (3.1–kb XhoI–SalI fragment from pLAc/env-
Tr712-neo, including the HIV env sequence).
Fluorescence-activated cell sorter (FACS) analysis
Green fluorescence protein expression was monitored by
a shift to green fluorescence (FL-1). FACS analysis was
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performed with FACScan (Becton Dickinson) using
Cellquest software.
Acknowledgments
We thank Catherine Haynes and Otto Erlwein for helpful
discussions and critically reading the manuscript.
References
Bieniasz, P.D., Grdina, T.A., Bogerd, H.P., Cullen, B.R., 1998. Recruit-
ment of a protein complex containing Tat and cyclin T1 to TAR
governs the species specificity of HIV-1 Tat. EMBO J. 17, 7056–7065.
Blot, G., Janvier, K., Le Panse, S., Benarous, R., Berlioz-Torrent, C., 2003.
Targeting of the human immunodeficiency virus type 1 envelope to the
trans-golgi network through binding to TIP47 is required for Env
incorporation into virions and infectivity. J. Virol. 77, 6931–6945.
Deng, H.K., Unutmaz, D., KewalRamani, V.N., Littman, D.R., 1997.
Expression cloning of new receptors used by simian and human im-
munodeficiency viruses. Nature 388, 296–300.
Erlwein, O., Buchholz, C.J., Schnierle, B.S., 2003. The proline-rich region
of the ecotropic Moloney murine leukaemia virus envelope protein
tolerates the insertion of the green fluorescent protein and allows the
generation of replication-competent virus. J. Gen. Virol. 84, 369–373.
Erlwein, O., Wels, W., Schnierle, B.S., 2002. Chimeric ecotropic MLV
envelope proteins that carry EGF receptor-specific ligands and the
Pseudomonas exotoxin A translocation domain to target gene transfer
to human cancer cells. Virology 302, 333–341.
Freed, E.O., Martin, M.A., 1996. Domains of the human immunodeficiency
virus type 1 matrix and gp41 cytoplasmic tail required for envelope
incorporation into virions. J. Virol. 70, 341–351.
Green, S., Issemann, I., Sheer, E., 1988. A versatile in vivo and in vitro
eukaryotic expression vector for protein engineering. Nucleic Acids
Res. 16, 369.
Hammarskjold, M.L., Li, H., Rekosh, D., Prasad, S., 1994. Human immu-
nodeficiency virus env expression becomes Rev-independent if the env
region is not defined as an intron. J. Virol. 68, 951–958.
Harbers, K., Schnieke, A., Stuhlmann, H., Jahner, D., Jaenisch, R., 1981.
DNA methylation and gene expression: endogenous retroviral genome
becomes infectious after molecular cloning. Proc. Natl. Acad. Sci. USA
78, 7609–7613.
Hohne, M., Thaler, S., Dudda, J.C., Groner, B., Schnierle, B.S., 1999.
Truncation of the human immunodeficiency virus-type-2 envelope gly-
coprotein allows efficient pseudotyping of murine leukemia virus ret-
roviral vector particles. Virology 261, 70–78.
Huang, Y., Wimler, K.M., Carmichael, G.G., 1999. Intronless mRNA
transport elements may affect multiple steps of pre-mRNA processing.
EMBO J. 18, 1642–1652.
Indraccolo, S., Minuzzo, S., Feroli, F., Mammano, F., Calderazzo, F.,
Chieco-Bianchi, L., Amadori, A., 1998. Pseudotyping of Moloney
leukemia virus-based retroviral vectors with simian immunodeficiency
virus envelope leads to targeted infection of human CD4 lymphoid
cells. Gene Ther. 5, 209–217.
Iwatani, Y., Ueno, T., Nishimura, A., Zhang, X., Hattori, T., Ishimoto, A.,
Ito, M., Sakai, H., 2001. Modification of virus infectivity by cytoplas-
mic tail of HIV-1 TM protein. Virus Res. 74, 75–87.
Killeen, N., Sawada, S., Littman, D.R., 1993. Regulated expression of
human CD4 rescues helper T cell development in mice lacking expres-
sion of endogenous CD4. EMBO J. 12, 1547–1553.
Lindemann, D., Bock, M., Schweizer, M., Rethwilm, A., 1997. Efficient
pseudotyping of murine leukemia virus particles with chimeric human
foamy virus envelope proteins. J. Virol. 71, 4815–4820.
Mammano, F., Salvatori, F., Indraccolo, S., De Rossi, A., Chieco-Bianchi,
L., Gottlinger, H.G., 1997. Truncation of the human immunodeficiency
virus type 1 envelope glycoprotein allows efficient pseudotyping of
Moloney murine leukemia virus particles and gene transfer into CD4
cells. J. Virol. 71, 3341–3345.
Mariani, R., Rutter, G., Harris, M.E., Hope, T.J., Krausslich, H.G., Landau,
N.R., 2000. A block to human immunodeficiency virus type 1 assembly
in murine cells. J. Virol. 74, 3859–3870.
Nasioulas, G., Zolotukhin, A.S., Tabernero, C., Solomin, L., Cunningham,
C.P., Pavlakis, G.N., Felber, B.K., 1994. Elements distinct from human
immunodeficiency virus type 1 splice sites are responsible for the Rev
dependence of env mRNA. J. Virol. 68, 2986–2993.
Ory, D.S., Neugeboren, B.A., Mulligan, R.C., 1996. A stable human-
derived packaging cell line for production of high titer retrovirus/
vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA
93, 11400–11406.
Pollard, V.W., Malim, M.H., 1998. The HIV-1 Rev protein. Annu. Rev.
Microbiol. 52, 491–532.
Popa, I., Harris, M.E., Donello, J.E., Hope, T.J., 2002. CRM1-dependent
function of a cis-acting RNA export element. Mol. Cell. Biol. 22,
2057–2067.
Reed, M., Mariani, R., Sheppard, L., Pekrun, K., Landau, N.R., Soong,
N.W., 2002. Chimeric human immunodeficiency virus type 1 contain-
ing murine leukemia virus matrix assembles in murine cells. J. Virol.
76, 436–443.
Rousso, I., Mixon, M.B., Chen, B.K., Kim, P.S., 2000. Palmitoylation of
the HIV-1 envelope glycoprotein is critical for viral infectivity. Proc.
Natl. Acad. Sci. USA 97, 13523–13525.
Schnierle, B.S., Moritz, D., Jeschke, M., Groner, B., 1996. Expression of
chimeric envelope proteins in helper cell lines and integration into
Moloney murine leukemia virus particles. Gene Ther. 3, 334–342.
Schnierle, B.S., Stitz, J., Bosch, V., Nocken, F., Merget-Millitzer, H.,
Engelstadter, M., Kurth, R., Groner, B., Cichutek, K., 1997. Pseudotyp-
ing of murine leukemia virus with the envelope glycoproteins of HIV
generates a retroviral vector with specificity of infection for CD4-
expressing cells. Proc. Natl. Acad. Sci. USA 94, 8640–8645.
Shinnick, T.M., Lerner, R.A., Sutcliffe, G.J., 1981. Nucleotide sequence of
Moloney murine leukaemia virus. Nature 293, 543–548.
Steffens, C.M., Hope, T.J., 2001. Recent advances in the understanding of
HIV accessory protein function. AIDS 15 (Suppl. 5), S21–S26.
Stitz, J., Steidl, S., Merget-Millitzer, H., Konig, R., Muller, P., Nocken, F.,
Engelstadter, M., Bobkova, M., Schmitt, I., Kurth, R., Buchholz, C.J.,
Cichutek, K., 2000. MLV-derived retroviral vectors selective for CD4-
expressing cells and resistant to neutralization by sera from HIV-
infected patients. Virology 267, 229–236.
Thaler, S., Schnierle, B.S., 2001. A packaging cell line generating CD4-
specific retroviral vectors for efficient gene transfer into primary human
T-helper lymphocytes. Mol. Ther. 4, 273–279.
Vogt, B., Roscher, S., Abel, B., Hildinger, M., Lamarre, A., Baum, C., von
Laer, D., 2001. Lack of superinfection interference in retroviral vector
producer cells. Hum. Gene Ther. 12, 359–365.
Wilk, T., Pfeiffer, T., Bosch, V., 1992. Retained in vitro infectivity and
cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of
the env gene product. Virology 189, 167–177.
Yu, X., Yuan, X., McLane, M.F., Lee, T.H., Essex, M., 1993. Mutations in
the cytoplasmic domain of human immunodeficiency virus type 1
transmembrane protein impair the incorporation of Env proteins into
mature virions. J. Virol. 67, 213–221.
Zufferey, R., Donello, J.E., Trono, D., Hope, T.J., 1999. Woodchuck
hepatitis virus posttranscriptional regulatory element enhances expres-
sion of transgenes delivered by retroviral vectors. J. Virol. 73, 2886–
2892.
216 U. Nack, B.S. Schnierle / Virology 315 (2003) 209–216
